Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025)

Heron Therapeutics (HRTX) has disclosed Amortization of Deferred Charges for 5 consecutive years, with -$35000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 166.04% year-over-year to -$35000.0, compared with a TTM value of $73000.0 through Dec 2025, down 65.24%, and an annual FY2025 reading of $73000.0, down 65.24% over the prior year.
  • Amortization of Deferred Charges was -$35000.0 for Q4 2025 at Heron Therapeutics, down from $2000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $55000.0 in Q3 2023 and bottomed at -$35000.0 in Q4 2025.
  • Average Amortization of Deferred Charges over 5 years is $43944.4, with a median of $51000.0 recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges increased 6.12% in 2024, then tumbled 166.04% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then rose by 2.0% to $51000.0 in 2023, then grew by 3.92% to $53000.0 in 2024, then crashed by 166.04% to -$35000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for HRTX at -$35000.0 in Q4 2025, $2000.0 in Q3 2025, and $53000.0 in Q2 2025.